natgillin/translations-raw huggingface dataset:
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8). 
Zaradi tveganja krvavitve in hematoloških neželenih učinkov moramo takoj pretehtati potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadarkoli se v času zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8).
Contact your doctor immediately if you experience: fever, signs of infection or extreme tiredness. 
Nemudoma se posvetujte s svojim zdravnikom, če se pri vas pojavijo: - zvišana telesna temperatura, znaki okužbe ali huda utrujenost.
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment. 
Krvavitve so bile najpogosteje opisan učinek tako v kliničnih študijah kot med postmarketinško uporabo, med katero so se najpogosteje pojavile prvi mesec zdravljenja.
Acino AG Am Windfeld 35 83714 Miesbach Germany 
Acino AG Am Windfeld 35 83714 Miesbach Nemčija
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel. 
Če se zahteva takojšnje korigiranje podaljšanega časa krvavitve, lahko transfuzija trombocitov deluje reverzno na učinek klopidogrela.
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular). 
Klopidogrel podaljša čas krvavitve in se mora uporabljati previdno pri bolnikih z lezijami, ki so nagnjene h krvavitvi (zlasti gastrointestinalne in intraokularne).
Do not use Clopidogrel Acino Pharma if you notice any visible sign of damage of blister or film-coated tablets. 
Ne uporabljajte zdravila Klopidogrel Acino Pharma, če ste opazili vidne znake poškodovanja pretisnega omota ali filmsko obloženih tablet.
Recent myocardial infarction (MI), recent stroke or established peripheral arterial disease 
Nedavni miokardni infarkt (MI), nedavna kap ali ugotovljena periferna arterijska bolezen
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%. 
V študiji CAPRIE je bila pri bolnikih, zdravljenih bodisi s klopidogrelom ali ASA, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
The most common side effect reported with clopidogrel is bleeding. 
Najpogostejši neželeni učinek, o katerem so poročali s klopidogrelom, je krvavitev.
• Active pathological bleeding such as peptic ulcer or intracranial haemorrhage. 
• Aktivna patološka krvavitev, kot je peptična razjeda ali intrakranialna krvavitev.
This is linked to the way your medicine works as it prevents the ability of blood clots to form. 
To je povezano z načinom delovanja zdravila, saj preprečuje strjevanje krvi.
The clinically relevant adverse reactions observed in the CAPRIE study are discussed below. 
Klinično pomembni neželeni učinki, zabeleženi v študiji CAPRIE, so predstavljeni spodaj.
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure. 
Ker kliničnih podatkov o izpostavljenosti klopidogrelu med nosečnostjo ni, je kot previdnostni ukrep zaželeno, da se klopidogrel v nosečnosti ne uporablja.
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk. 
Specifične farmakokinetične študije, izvedene z radioaktivno označenim klopidogrelom, so pokazale, da se izhodna spojina ali njeni metaboliti izločajo v mleko.
Apart from the specific medicinal products interaction information described above, interaction studies with clopidogrel and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed. 
Razen zgoraj navedenih podatkov o specifičnih interakcijah z zdravili, študij o interakcijah klopidogrela z nekaterimi drugimi zdravili, ki jih bolniki z aterotrombotično boleznijo pogosto uporabljajo, niso izvedli.
• Paediatric population • Clopidogrel should not be used in children because of efficacy concerns (see section 5.1). 
• Pediatrična populacija Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1.
Glomerulonephritis, blood creatinine increased 
Glomerulonefritis, zvišanje kreatinina v krvi
When given to lactating rats, clopidogrel caused a slight delay in the development of the offspring. 
Ko so ga dajali doječim podganam, je klopidogrel povzročil blago zakasnitev razvoja mladičkov.
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation. 
Heparin: v klinični študiji, izvedeni pri zdravih osebah, klopidogrel ni zahteval spremembe odmerka heparina ali spremenil učinka heparina na koagulacijo.
If you have a medical condition that is currently causing bleeding such as a stomach ulcer or bleeding within the brain; 
• če imate zdravstveno stanje, ki trenutno povzroča krvavitev, kot je rana na želodcu ali krvavitev v možganih;
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits. 
Ugotovili so, da klopidogrel nima vpliva na plodnost podganjih samcev in samic in ni teratogen niti za podgane ali kunce.
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 
• bolnikih z miokardnim infarktom (od nekaj dni do manj kot 35 dni), ishemično kapjo (od 7 dni do manj kot 6 mesecev) ali dokazano periferno arterijsko boleznijo.
Excipients: each film-coatedtablet contains 3.80 mg of hydrogenated castor oil. 
Pomožne snovi: vsaka filmsko obložena tableta vsebuje 3,80 mg hidrogeniranega ricinusovega olja.
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04. 
Farmakoterapevtska skupina: Zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC04.
Elimination Following an oral dose of 14C-labelled clopidogrel in man, approximately 50% was excreted in the urine and approximately 46% in the faeces in the 120-hour interval after dosing. 
Eliminacija Po peroralnem odmerku s 14C-označenega klopidogrela pri človeku, se ga je približno 50 % izločilo z urinom in približno 46 % z blatom v 120 urnem intervalu po odmerjanju.
Pregnancy and breast-feeding It is preferable not to take this product during pregnancy. 
Nosečnost in dojenje Priporočljivo je, da se tega zdravila v nosečnosti ne uporablja.
Other concomitant therapy: 
Drugo sočasno zdravljenje:
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern. 
Pri manjših vrezninah ali poškodbah, npr. če se urežete ali brijete, to navadno ni zaskrbljujoče.
Bleeding may occur as bleeding in the stomach or bowels, bruising, haematoma (unusual bleeding or bruising under the skin), nose bleed, blood in the urine. 
Krvavitve se lahko pojavijo kot krvavitve iz želodca ali črevesja, kot modrice, hematomi (neobičajne krvavitve ali modrice pod kožo), krvavitev iz nosu, kri v urinu.
There was no evidence of carcinogenic effect when clopidogrel was administered for 78 weeks to mice and 104 weeks to rats when given at doses up to 77 mg/kg per day (representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day). 
Ni bilo dokazov o kancerogenem učinku pri dajanju klopidogrela mišim 78 tednov in podganam 104 tedne v odmerkih do 77 mg/kg na dan (kar predstavlja najmanj 25-krat višjo izpostavljenost kot pri človeku ob prejemanju kliničnega odmerka 75 mg/dan).
If you take more Clopidogrel Acino Pharma than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding. 
Če ste vzeli večji odmerek zdravila Klopidogrel Acino Pharma, kot bi smeli Zaradi povečanega tveganja krvavitve se posvetujte s svojim zdravnikom ali oddelkom najbližje bolnišnične nujne zdravniške pomoči.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction. 
Trombolitiki: varnost sočasne uporabe klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ovrednotena pri bolnikih z akutnim miokardnim infarktom.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition. 
Ker aktivni presnovek nastane z delovanjem encimov CYP450, od katerih so nekateri polimorfni ali podvrženi zavrtju z drugimi zdravili, se ustrezno zavrtje trombocitov ne pojavi pri vseh bolnikih.
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called thrombosis). 
S preprečevanjem tega zlepljanja, zaviralci agregacije trombocitov zmanjšajo možnost nastanka krvnih strdkov (proces se imenuje tromboza).
It also contains hydrogenated castor oil. 
SEZNAM POMOŽNIH SNOVI Vsebuje tudi hidrogenirano ricinusovo olje.
The usual dose is one 75 mg tablet of Clopidogrel Acino Pharma per day to be taken orally with or without food, and at the same time each day. 
Običajni odmerek je ena 75-mg tableta zdravila Klopidogrel Acino Pharma na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
During non clinical studies in rat and baboon, the most frequently observed effects were liver changes. 
V predkliničnih študijah na podganah in pavijanih, so bile jetrne spremembe najpogosteje opaženi učinek.
At steady state, the average inhibition level observed with a dose of 75 mg per day was between 40% and 60%. 
V stanju dinamičnega ravnovesja je bila povprečno opažena raven zaviranja z odmerkom 75 mg na dan med 40 % in 60 %.
Due to the irreversible binding, platelets exposed are affected for the remainder of their lifespan (approximately 7 - 10 days) and recovery of normal platelet function occurs at a rate consistent with platelet turnover. 
Zaradi ireverzibilne vezave se učinek na izpostavljene trombocite ohrani vso njihovo preostalo življenjsko dobo (približno 7-10 dni) in normalno delovanje trombocitov se obnovi s hitrostjo, ki je v skladu s premeno trombocitov.
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8) 
Incidenca klinično pomembnih krvavitev je bila podobna tisti, ki so jo opazili pri uporabi trombolitikov in heparina sočasno z ASA (glejte poglavje 4.8).
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers. 
Na račun alelov CYP2C19*2 in CYP2C19*3 gre večina alelov z zmanjšanim delovanjem pri Kavkazijcih (85%) in pri Azijcih (99 %), ki so slabi metabolizatorji.
Patients were randomised to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years. 
Bolniki so bili naključno razdeljeni v skupine, ki so prejemale klopidogrel 75 mg/dan ali ASA 325 mg/dan, spremljali so jih od 1 do 3 let.
Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu/ 
DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu/.
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (< 35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD). 
Študija CAPRIE je vključevala 19.185 bolnikov z aterotrombozo, ki se je odrazila z nedavnim miokardnim infarktom (< 35 dni), ishemično kapjo (med 7 dni in 6 meseci) ali razvito periferno arterijsko boleznijo (PAD).
Platelets (so-called thrombocytes) are very small structures, which clump together during blood clotting. 
Trombociti so zelo majhne strukture, ki se zlepljajo pri strjevanju krvi.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of clopidogrel. 
Ni dokazov, da druga zdravila za zmanjševanje želodčne kisline, npr. antagonisti histaminskih receptorjev H2 (razen cimetidina, ki je CYP2C19 inhibitor) ali antacidi, ovirajo antitrombocitno delovanje klopidogrela.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]). 
Pri bolnikih, ki so bili vključeni v preskušanje samo na podlagi nedavnega miokardnega infarkta, je bil klopidogrel numerično inferioren, vendar se statistično ni razlikoval od ASA (zmanjšanje RT= -4,0 %; IZ: -22,5 do 11,7 [p=0,639]).
Retroperitoneal haemorrhage 
Retroperitonealna krvavitev
They are supplied in cardboard cartons containing 14, 28, 30, 50, 84, 90 and 100 tablets in aluminium blisters. 
Na voljo so v škatlah, ki vsebujejo 14, 28, 30, 50, 84, 90 in 100 tablet v pretisnih omotih iz aluminija.
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no genotoxic activity. 
Klopidogrel so preizkušali v številnih in vitro ter in vivo študijah genotoksičnosti in ni pokazal nobenega genotoksičnega učinka.
Alu/Alu blisters containing 14, 28, 30, 50, 84, 90 and 100 film-coated tablets packed in cardboard cartons. 
Alu/Alu pretisni omoti, ki vsebujejo 14, 28, 30, 50, 84, 90 in 100 filmsko obloženih tablet v kartonskih škatlah.
Like all medicines, Clopidogrel Acino Pharma can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Klopidogrel Acino Pharma neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
These occurred at doses representing at least 25 times the exposure seen in humans receiving the clinical dose of 75 mg/day and were a consequence of an effect on hepatic metabolising enzymes. 
Pojavile so se pri odmerkih, ki predstavljajo najmanj 25-kratno izpostavljenost kot pri človeku ob prejemanju kliničnega odmerka 75 mg/dan in so bile posledica učinka na jetrne presnovne encime.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation. 
Acetilsalicilna kislina (ASA): ASA ni spremenila s klopidogrelom dosežene inhibicije z ADP-jem sprožene agregacije trombocitov, vendar klopidogrel ojača učinek ASA na s kolagenom sproženo agregacijo trombocitov.
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘POSSIBLE SIDE EFFECTS'). 
• morate takoj povedati zdravniku, če razvijete bolezensko stanje (znano tudi kot trombotična trombocitopenična purpura ali TTP) z zvišano telesno temperaturo in modricami pod kožo, ki se lahko pojavijo kot drobne rdeče pike, z ali brez nerazložljive hude utrujenosti, zmedenosti, porumenele kože ali oči (zlatenica) (glejte poglavje 4 »MOŽNI NEŽELENI UČINKI«).
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel Acino Pharma. 
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden boste vzeli Klopidogrel Acino Pharma.
If you become pregnant while taking Clopidogrel Acino Pharma, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
Če med zdravljenjem z zdravilom Klopidogrel Acino Pharma zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
- For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose. 
- če je zamuda več kot 12 ur: bolnik naj naslednji odmerek vzame ob pravem času; odmerka ne sme podvojiti.
Taking Clopidogrel Acino Pharma with food and drink Clopidogrel Acino Pharma may be taken with or without food. 
Jemanje zdravila Klopidogrel Acino Pharma skupaj s hrano in pijačo Zdravilo Klopidogrel Acino Pharma lahko jemljete s hrano ali brez nje.
White to off-white, marbled, round and biconvex film-coated tablets. 
Bele do belkaste, marmorirane, okrogle, bikonveksne filmsko obložene tablete.
If you forget to take a dose of Clopidogrel Acino Pharma, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time. 
Če ste pozabili vzeti zdravilo Klopidogrel Acino Pharma Če pozabite vzeti odmerek zdravila Klopidogrel Acino Pharma in se nanj spomnite do 12 ur po ustaljenem času, takoj vzemite tableto in nato vzemite naslednjo tableto spet ob ustaljenem času jemanja.
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever. 
Zanjo je značilna trombocitopenija in mikroangiopatična hemolitična anemija povezana bodisi z nevrološkimi spremembami, motnjo v delovanju ledvic ali vročino.
Other side effects reported with Clopidogrel Acino Pharma are: -Common side effects: 
Drugi neželeni učinki, o katerih so poročali s Klopidogrel Acino Pharma, so: - Pogosti neželeni učinki:
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported. 
V majhnem številu primerov so poročali tudi o očesnih krvavitvah, krvavitvah v glavi, pljučih ali sklepih.
Appropriate therapy should be considered if bleedings are observed. 
V primeru krvavitev je potrebno zagotoviti ustrezno zdravljenje.
Acute liver failure, hepatitis, abnormal liver function test 
Akutna odpoved jeter, hepatitis, nenormalni testi jetrne funkcije
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA. 
Klopidogrel je pomembno zmanjšal incidenco novih ishemičnih dogodkov (sestavljen opazovani dogodek miokardni infarkt, ishemična kap in žilna smrt) v primerjavi z ASA.
Driving and using machines Clopidogrel Acino Pharma is unlikely to affect your ability to drive or to use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi zdravilo Klopidogrel Acino Pharma vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
If you experience prolonged bleeding when taking Clopidogrel Acino Pharma. 
Če doživite podaljšanje krvavitve v času jemanja zdravila Klopidogrel Acino Pharma.
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4). 
Zaradi tega moramo NSAIDs, vključno s COX2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4).
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Acino Pharma. 
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Klopidogrel Acino Pharma.
Contact your doctor or pharmacist before stopping. 
Posvetujte se s svojim zdravnikom ali farmacevtom, preden prekinete zdravljenje.
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel. 
Sočasna uporaba heparina ni imela nobenega učinka na inhibicijo agregacije trombocitov, sprožene s klopidogrelom.
Clopidogrel Acino Pharma is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
Zdravilo Klopidogrel Acino Pharma se jemlje za preprečevanje nastanka krvnih strdkov (trombov) v otrdelih krvnih žilah (arterijah), proces je znan kot aterotromboza in lahko vodi do aterotrombotičnih dogodkov (kot so kap, srčni napad ali smrt).
You should take Clopidogrel Acino Pharma for as long as your doctor continues to prescribe it. 
Zdravilo Klopidogrel Acino Pharma morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
However, if you are concerned by your bleeding, you should contact your doctor straightaway (see section 4 ‘POSSIBLE SIDE EFFECTS'). 
Če pa vas glede krvavitve skrbi, se nemudoma posvetujte z zdravnikom (glejte poglavje 4 »MOŽNI NEŽELENI UČINKI«).
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia 
Mišično-skeletne krvavitve (hemartroza), artritis, artralgija, mialgija
Experience is limited in patients with moderate hepatic disease who may have bleeding diatheses. 
Izkušnje so omejene pri populaciji z zmerno jetrno boleznijo, ki imajo lahko hemoragično diatezo.
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Če bolnik izpusti odmerek: - če je zamuda manj kot 12 ur po pravem času: bolnik naj odmerek vzame takoj, potem pa naslednji odmerek ob pravem času.
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose. 
Nobenega učinka na presnovne encime niso opazili pri ljudeh ob prejemanju terapevtskih odmerkov.
What Clopidogrel Acino Pharma is and what it is used for Before you take Clopidogrel Acino Pharma How to take Clopidogrel Acino Pharma Possible side effects 
Kaj je zdravilo Klopidogrel Acino Pharma in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Klopidogrel Acino Pharma Kako jemati zdravilo Klopidogrel Acino Pharma Možni neželeni učinki
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. 
Pri analizi vključenih bolnikov (“intention to treat analysis”) so v skupini, ki je prejemala klopidogrel, opazili 939 dogodkov in v skupini, ki je prejemala ASA, 1.020 dogodkov (zmanjšanje relativnega tveganja (RT) 8,7 %, [95 % IZ: 0,2 do 16,4]; p=0,045), kar ustreza preprečevanju pojava novega ishemičnega dogodka na vsakih 1.000 bolnikov, zdravljenih 2 leti, dodatnim 10 [IZ: 0 do 20] bolnikom.
If you stop taking Clopidogrel Acino Pharma Do not stop the treatment unless your doctor tells you so.. 
Če ste prenehali jemati zdravilo Klopidogrel Acino Pharma Ne prekinite zdravljenjaa razen, če tako odloči zdravnik.
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital or oestrogen. 
Poleg tega na farmakodinamično aktivnost klopidogrela ni pomembno vplivala sočasna uporaba fenobarbitala ali estrogena.
HOW TO STORE CLOPIDOGREL ACINO PHARMA Store in the original blister in order to protect from moisture. 
SHRANJEVANJE ZDRAVILA KLOPIDOGREL ACINO PHARMA Shranjujte v originalnem pretisnem omotu za zagotovitev zaščite pred vlago.
Glycoprotein IIb/IIIa inhibitors: clopidogrel should be used with caution in patients who receive concomitant glycoprotein IIb/IIIa inhibitors (see section 4.4). 
Zaviralci glikoproteina IIb/IIIa: klopidogrel moramo uporabljati previdno pri bolnikih, ki prejemajo sočasno zaviralce glikoproteina IIb/IIIa (glejte poglavje 4.4).
The incidence of severe cases was similar for clopidogrel and 1.6% for ASA. 
Incidenca hujših primerov je bila podobna za klopidogrel in za ASA.
Taste disturbances 
Motnje okusa